Latest filing published 11 Jun 2024 for Cullinan Therapeutics, Inc., €223k.
Insider track record
Thomas Ebeling: trading record in brief
Thomas Ebeling discloses dealings in Cullinan Therapeutics, Inc. to SEC (Form 4). In total, 3 filings cover trades dated from 23 May 2024 to 10 June 2024.
No open-market purchase or sale appears among the filings, only grants, plan transactions and other operations. Compensation-driven entries like these are tracked, but they say little about how insiders judge the share price.
On 11 June 2024 came the latest disclosure, an option exercise for €223k in Cullinan Therapeutics, Inc. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Companies and markets linked to Thomas Ebeling
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 18,450 shares@ US$13.0039.9% of flowCommon StockSEC:0000950170-24-072095:0
- 16,475 shares@ US$12.7325.8% of flowCommon StockSEC:0000950170-24-063948:1
- 84,224 shares@ US$4.3060.1% of flowCommon StockSEC:0000950170-24-063948:0
3 of 3 declarations
